| Li, Jingao |
NCT06277050: Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 264 | RoW | Maintenance Therapy with Toripalimab and Capecitabine, Maintenance Therapy with Capecitabine | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma, High-Risk Cancer, Maintenance Therapy | 02/29 | 02/30 | | |
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 864 | Europe, Canada, Japan, US, RoW | Dostarlimab, Placebo | GlaxoSmithKline | Neoplasms, Head and Neck | 05/28 | 07/29 | | |
NCT05893810: Bacterial Decolonization to Prevent Radiation-induced Oral Mucositis |
|
|
| Recruiting | 3 | 176 | RoW | Mupirocin Ointment | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma, Radiation-induced Oral Mucositis, Bacterial Colonization, Quality of Life | 04/24 | 12/24 | | |
| Terminated | 3 | 166 | Europe, Canada, Japan, US, RoW | Xevinapant (Debio 1143), IMRT, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Head and Neck Cancer | 08/24 | 08/24 | | |
NCT03907826: PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients |
|
|
| Recruiting | 3 | 212 | RoW | PD-1 blocking antibody, JS001, GP, IMRT | Sun Yat-sen University | Recurrent Nasopharyngeal Carcinoma | 12/24 | 12/27 | | |
NCT05340491: Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial |
|
|
| Recruiting | 3 | 212 | RoW | Toripalimab, JS001, Chemotherapy, GP, Intensity modulated radiotherapy, IMRT | Sun Yat-sen University | Nasopharyngeal Carcinoma | 12/24 | 12/27 | | |
NCT04557020: Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC |
|
|
| Recruiting | 3 | 200 | RoW | PD-1 antibody, Gemcitabine, Cisplatin, IMRT | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma | 03/26 | 03/26 | | |
NCT05780372: Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 474 | RoW | Intensity Modulated Radiation Therapy, IMRT, Chemotherapy | Sun Yat-sen University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Chongqing University Cancer Hospital, Dongguan People's Hospital, LiuZhou People's Hospital | Nasopharyngeal Carcinoma, Radiotherapy; Complications | 08/26 | 08/29 | | |
NCT05941741: IC Plus Low-dose Radiation Plus Cadonilimab in LANPC |
|
|
| Recruiting | 3 | 380 | RoW | Intensity Modulated Radiation Therapy, IMRT, Chemotherapy, Induction chemotherapy, Concurrent chemotherapy, Gemcitabine, Cisplatin, Immune checkpoint inhibitor, Cadonilimab, AK104, PD-1/CTLA-4 inhibitor, Low-dose radiotherapy | Sun Yat-sen University | Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy | 12/26 | 12/29 | | |
NCT06259721: Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 22 | RoW | Anti-PD1 antibody, nimotuzumab and capecitabine | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma | 02/26 | 08/26 | | |
ST-CR01, NCT05755009: High- and Low-dose Radiotherapy Combined With Envafolimab for Metastatic Solid Tumor |
|
|
| Recruiting | 2 | 33 | RoW | High- and Low-dose radiotherapy | Jiangxi Provincial Cancer Hospital | Metastatic Cancer | 02/24 | 02/25 | | |
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 238 | RoW | MRG003, Capecitabine tablets, Docetaxel injection | Shanghai Miracogen Inc. | Recurrent or Metastatic Nasopharyngeal Carcinoma | 10/24 | 02/25 | | |
NPC-CR01, NCT05128201: Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 63 | RoW | consolidative radiotherapy, local consolidative radiotherapy | Jiangxi Provincial Cancer Hospital | Oligometastatic Disease | 05/25 | 05/26 | | |
NCT06214143: A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 68 | RoW | T3011 high dose, T3011 middle dose, T3011 low dose | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumors | 12/25 | 05/26 | | |
TQB2618-AK105-Ib-02, NCT05783921: A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 1/2 | 60 | RoW | TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma | 08/24 | 01/25 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT06268600: The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 320 | RoW | Modified neck target volume delineation | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Hypothyroidism | 11/24 | 11/25 | | |
NCT06182657: The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC |
|
|
| Recruiting | N/A | 300 | RoW | | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma, Pathologic Complete Response, Tumor Microenvironment | 06/27 | 06/29 | | |
| Wu, Wei |
| Not yet recruiting | 4 | 336 | RoW | Danning Tablet, Biliflow (NPN 80073325, manufactured by Shanghai Hutchison Pharmaceuticals Limited) | Eastern Hepatobiliary Surgery Hospital | Polyps Gallbladder | 08/24 | 11/24 | | |
NCT03236636: The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects |
|
|
| Recruiting | 3 | 312 | RoW | Icaritin, SNG-162, HUACHANSU PIAN, HUACHANSU PIAN（999） | Beijing Shenogen Biomedical Co., Ltd, Chinese Academy of Medical Sciences, NanJing PLA 81 Hospital, Peking University Cancer Hospital & Institute, Beijing Hospital, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Tumour Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Hebei Medical University Fourth Hospital, The First Hospital of Jilin University, Haikou People's Hospital, Fudan University, West China Hospital, Chongqing Traditional Chinese Medicine Hospital, Chifeng Municipal Hospital, The Affiliated Hospital of Hangzhou Normal University, The First Affiliated Hospital of Zhengzhou University, Guilin Medical University, China, The Third Xiangya Hospital of Central South University, Yunnan Provincial Hospital of Traditional Chinese Medicine, The Sixth People's Hospital of Shenyang | Advanced HBV-Related Hepatocellular Carcinoma (HCC) | 12/22 | 12/22 | | |
NCT05745259: Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ） |
|
|
| Recruiting | 3 | 1630 | RoW | Alteplase, rt-PA, Tenecteplase, TNK-tPA | Beijing Tiantan Hospital, Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd, The Place Pharmaceutical(Jiangsu) Co., Ltd | Acute Ischemic Stroke | 11/23 | 03/24 | | |
SHINY, NCT06157502: Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Shuxuening Injection, Placebo | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 06/25 | 12/26 | | |
NCT06277050: Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 264 | RoW | Maintenance Therapy with Toripalimab and Capecitabine, Maintenance Therapy with Capecitabine | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma, High-Risk Cancer, Maintenance Therapy | 02/29 | 02/30 | | |
TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 12/25 | 12/26 | | |
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. |
|
|
| Recruiting | 3 | 480 | RoW | Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 12/26 | | |
NCT04557020: Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC |
|
|
| Recruiting | 3 | 200 | RoW | PD-1 antibody, Gemcitabine, Cisplatin, IMRT | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma | 03/26 | 03/26 | | |
NCT04741165: Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 2 | 72 | RoW | HX008, Bevacizumab, AVASTIN®, Lenvatinib, LENVIMA® | Taizhou Hanzhong biomedical co. LTD | Hepatocellular Carcinoma | 04/22 | 10/22 | | |
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 238 | RoW | MRG003, Capecitabine tablets, Docetaxel injection | Shanghai Miracogen Inc. | Recurrent or Metastatic Nasopharyngeal Carcinoma | 10/24 | 02/25 | | |
NPC-CR01, NCT05128201: Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 63 | RoW | consolidative radiotherapy, local consolidative radiotherapy | Jiangxi Provincial Cancer Hospital | Oligometastatic Disease | 05/25 | 05/26 | | |
NCT05339321: Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC |
|
|
| Recruiting | 1 | 36 | RoW | SCG101, PD1/PD-L1 checkpoint inhibitor | Peking Union Medical College Hospital | Hepatocellular Carcinoma | 07/23 | 12/23 | | |
| Recruiting | 1 | 160 | US | Abstinence from alcohol, Usual drinking, Intravenous Alcohol, 6.0& (v/V) ethanol solution | Indiana University, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use Disorder | 08/25 | 08/25 | | |
TQB2618-AK105-Ib-04, NCT05975645: A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). |
|
|
| Recruiting | 1 | 40 | RoW | Penpulimab injection, TQB2618 injection, Anlotinib Hydrochloride Capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma | 12/24 | 04/25 | | |
NCT06375538: Ultrasound Evaluations of Diaphragm and Intercostal Muscle to Predict the Failure of High-Flow Nasal Cannula Therapy |
|
|
| Recruiting | N/A | 200 | RoW | | Shanghai Zhongshan Hospital | High-flow Nasal Cannula, Ultrasound Evaluation, Diaphragm and Intercostal Muscle | 08/25 | 12/25 | | |
| Recruiting | N/A | 100 | RoW | Automated peritoneal dialysis, Intermittent hemodialysis | Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation | Acute Kidney Injury | 12/22 | 12/22 | | |
| Recruiting | N/A | 206 | RoW | automated peritoneal dialysis, IHD | Peking Union Medical College Hospital, First Hospital of China Medical University, Beijing Anzhen Hospital, The Luhe Teaching Hospital of the Capital Medical University, Ningbo No.2 Hospital | ESRD | 12/22 | 02/23 | | |
NCT04353063: Muscle Wasting in Children and Adolescents With Cancer |
|
|
| Recruiting | N/A | 440 | RoW | Multidisciplinary care with a personalized care | National Taiwan University Hospital | Cachexia; Cancer, Muscle Wasting, Child Development, Adolescent Development | 07/23 | 07/23 | | |
NCT04724148: Impact of Fentanyl Analgesia on the Accuracy of HVPG Measurements in Patients With Portal Hypertension |
|
|
| Recruiting | N/A | 4 | RoW | Fentanyl | Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Lishui hospital of Zhejiang University, The First Affiliated Hospital with Nanjing Medical University, Zhejiang University | Liver Cirrhosis, Portal Hypertension, Pain | 11/24 | 11/24 | | |
NCT05316311: A Study of Implantation of CRENEOUS ENTERPRISE 2 Intracranial Stent in Participants With Severe Symptomatic Intracranial Atherosclerotic Stenosis |
|
|
| Recruiting | N/A | 194 | RoW | CERENOVUS ENTERPRISE 2 Intracranial Stent | Medos International SARL | Intracranial Atherosclerosis | 02/26 | 04/26 | | |
| Zhang, Dongsheng |
CLASSIC, NCT04262635: Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 3 | 80 | RoW | Cetuximab, Capecitabine, Cetuximab | Sun Yat-sen University | Colorectal Cancer | 12/22 | 08/24 | | |
NCT04557020: Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC |
|
|
| Recruiting | 3 | 200 | RoW | PD-1 antibody, Gemcitabine, Cisplatin, IMRT | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma | 03/26 | 03/26 | | |
NCT05163483: Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer |
|
|
| Recruiting | 2 | 87 | RoW | Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab, Tucidinostat (chidamide) JS001 | Ruihua Xu | Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma | 12/23 | 12/25 | | |
NCT06433869: The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites |
|
|
| Recruiting | 2 | 60 | RoW | serplulimab, PD-1 inhibitor, Bevacizumab, rmhTNF-NC, recombinant human tumor necrosis factor | Sun Yat-sen University | Malignant Ascites | 12/26 | 12/26 | | |
NCT05235906: A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 61 | RoW | Surufatinib+Sintilimab | Sun Yat-sen University | Gastric Adenocarcinoma | 03/24 | 03/25 | | |
NCT05481463: Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 20 | RoW | Surufatinib, TAS-102 | Sun Yat-sen University | Pancreatic Neoplasms | 08/24 | 08/25 | | |
NCT05481476: Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer |
|
|
| Recruiting | 2 | 32 | RoW | Surufatinib, Sintilimab, AG | Sun Yat-sen University | Pancreatic Neoplasms | 08/24 | 08/25 | | |
NCT05994456: Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer |
|
|
| Recruiting | 2 | 24 | RoW | PD-1 inhibitor, Toripalimab | Sun Yat-sen University | Gastric or Gastroesophageal Junction Adenocarcinoma | 12/24 | 12/24 | | |
NCT05742750: A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer |
|
|
| Not yet recruiting | 1/2 | 48 | RoW | Camrelizumab and Apatinib Plus GP, Apatinib (Apatinib Mesylate Tablets, Jiangsu Hengrui Medicine, China), Camrelizumab (Carelizumab for Injection, Jiangsu Hengrui Medicine, China) | Sun Yat-sen University, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer | 12/23 | 12/24 | | |
| Recruiting | N/A | 10254 | RoW | | Limeng Chen | Chronic Kidney Diseases, Chronic Kidney Disease-Mineral and Bone Disorder | 12/24 | 12/24 | | |
NCT05731336: A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan. |
|
|
| Recruiting | N/A | 500 | RoW | | Sun Yat-sen University | Advanced Colorectal Cancer | 05/25 | 05/26 | | |
NCT04572594: Molecular Profiling and Molecular Labeling of Inflammatory Myofibroblastic Tumor |
|
|
| Recruiting | N/A | 29 | RoW | | Sun Yat-sen University | Inflammatory Myofibroblatic Tumor | 01/21 | 01/21 | | |
| LIN, SHAOJUN |
| Recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | NBTXR3, Functionalized hafnium oxide nanoparticles, Cetuximab, Erbitux, Radiation Therapy | Nanobiotix | Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged | 06/26 | 06/27 | | |
| Terminated | 3 | 166 | Europe, Canada, Japan, US, RoW | Xevinapant (Debio 1143), IMRT, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Head and Neck Cancer | 08/24 | 08/24 | | |
NCT03907826: PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients |
|
|
| Recruiting | 3 | 212 | RoW | PD-1 blocking antibody, JS001, GP, IMRT | Sun Yat-sen University | Recurrent Nasopharyngeal Carcinoma | 12/24 | 12/27 | | |
NCT05340491: Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial |
|
|
| Recruiting | 3 | 212 | RoW | Toripalimab, JS001, Chemotherapy, GP, Intensity modulated radiotherapy, IMRT | Sun Yat-sen University | Nasopharyngeal Carcinoma | 12/24 | 12/27 | | |
NCT06095154: CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 3 | 474 | NA | CTV Delineation Based on Geometric Expansion From GTV in Nasopharyngeal Carcinoma | Fujian Cancer Hospital | Nasopharyngeal Carcinoma by AJCC V8 Stage | 12/27 | 12/30 | | |
NCT05519956: Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines |
|
|
| Not yet recruiting | 3 | 398 | NA | level Ib-covering IMRT, level Ib-sparing IMRT | Fujian Cancer Hospital | Nasopharyngeal Carcinoma | 09/25 | 09/25 | | |
NCT04557020: Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC |
|
|
| Recruiting | 3 | 200 | RoW | PD-1 antibody, Gemcitabine, Cisplatin, IMRT | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma | 03/26 | 03/26 | | |
NCT03666221: Nimotuzumab for Recurrent Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 67 | RoW | Nimotuzumab, Radiation | Fujian Cancer Hospital, Sun Yat-sen University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Fujian Medical University Union Hospital | Recurrent Nasopharyngeal Carcinoma | 04/20 | 11/22 | | |
NCT04421469: Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC |
|
|
| Not yet recruiting | 2 | 39 | RoW | Triprilimab(JS001) | Fujian Cancer Hospital, Zhejiang Cancer Hospital, Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma | 04/23 | 06/23 | | |
NCT04220528: Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC |
|
|
| Recruiting | 2 | 129 | RoW | Capecitabine/Tiggio, Radiation | Fujian Cancer Hospital, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 06/23 | 12/23 | | |
NCT05372120: A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations |
|
|
| Recruiting | 2 | 200 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Advanced Solid Tumor | 12/23 | 06/24 | | |
NPC-CR01, NCT05128201: Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 63 | RoW | consolidative radiotherapy, local consolidative radiotherapy | Jiangxi Provincial Cancer Hospital | Oligometastatic Disease | 05/25 | 05/26 | | |
NCT04745741: Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC |
|
|
| Not yet recruiting | N/A | 200 | RoW | IB-positive group | Fujian Cancer Hospital | Nasopharyngeal Carcinoma | 05/21 | 06/21 | | |
NCT04823468: Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 214 | RoW | Abbott®Ensure, Intensity Modulated Radiation Therapy, cisplatin | Jinsheng Hong, Fujian Cancer Hospital, The Second Affiliated Hospital of Fujian Medical University, The Nanping First Affiliated Hospital of Fujian Medical University, Quanzhou First Hospital Affiliated to Fujian Medical University, Fujian Medical University Union Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University, Hunan Cancer Hospital, Jiangxi Provincial Cancer Hospital, 900th hospital of the joint logistics team, PLA, Nanfang Hospital, Southern Medical University, The First Affiliated Hospital of Xiamen University, Zhongshan Hospital Xiamen University | Nasopharyngeal Carcinoma, Nutritional Support | 07/25 | 09/25 | | |
NCT06136962: Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life |
|
|
| Not yet recruiting | N/A | 500 | RoW | | Fujian Cancer Hospital | Nasopharyngeal Carcinoma | 12/24 | 12/24 | | |
| Li, Guiling |
| Active, not recruiting | 3 | 502 | Europe, Canada, Japan, US, RoW | tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed | Seagen Inc., Genmab | Cervical Cancer | 07/23 | 08/25 | | |
MRG002-006, NCT04839510: A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer |
|
|
| Recruiting | 2 | 58 | RoW | MRG002 | Shanghai Miracogen Inc. | Locally Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma | 06/22 | 09/22 | | |
NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer |
|
|
| Recruiting | 2 | 108 | RoW | Envafolimab+Lenvatinib, Envafolimab | 3D Medicines (Sichuan) Co., Ltd. | Advanced Endometrial Cancer | 08/24 | 10/24 | | |
NCT06173037: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer |
|
|
| Recruiting | 2 | 88 | RoW | RC88, RC88 for Injection | RemeGen Co., Ltd. | Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer | 06/26 | 12/26 | | |
NCT06434610: A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. |
|
|
| Recruiting | 2 | 90 | RoW | B013, Paclitaxel, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Platinum-resistant Recurrent Ovarian Cancer | 12/26 | 12/26 | | |
NCT05444374: A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer |
|
|
| Not yet recruiting | 2 | 48 | RoW | Serplulimab, Bevacizumab | Sichuan Cancer Hospital and Research Institute | Cervical Cancer | 09/24 | 12/25 | | |
| Recruiting | 2 | 184 | Europe, Canada, US, RoW | SKB264, Pembrolizumab, Keytruda | Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc. | Solid Tumor | 09/25 | 11/25 | | |
NCT06014190: HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer |
|
|
| Recruiting | 2 | 460 | RoW | HS-20089 | Hansoh BioMedical R&D Company | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer | 12/25 | 12/27 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT04322006: A Phase I/II Study of TJ004309 for Advanced Solid Tumor |
|
|
| Active, not recruiting | 1/2 | 376 | RoW | TJ004309, Toripalimab | TJ Biopharma Co., Ltd. | Advanced Solid Tumor | 12/24 | 12/24 | | |
| Active, not recruiting | 1/2 | 49 | Europe, Japan, US, RoW | TAK-981, Pembrolizumab | Takeda, Takeda Development Center Americas, Inc. | Advanced or Metastatic Solid Tumors | 11/25 | 11/25 | | |
NCT04718376: A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer |
|
|
| Terminated | 1 | 56 | RoW | Mitoxantrone Hydrochloride Liposome, intravenous injection (IV) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Platinum-resistant Ovarian Cancer | 05/23 | 05/23 | | |
WEE1, NCT04768868: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 350 | US, RoW | IMP7068 | Impact Therapeutics, Inc., Covance | Advanced Solid Tumors | 04/23 | 08/23 | | |
NCT04956926: Clinical Study of JS201 in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1 | 244 | RoW | JS201 | Shanghai Junshi Bioscience Co., Ltd. | Patients With Advanced Malignant Tumors | 07/23 | 07/23 | | |
NCT04606472: A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 159 | RoW | SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Solid Tumor | 06/25 | 06/25 | | |
NCT05866354: To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies |
|
|
| Completed | 1 | 19 | RoW | Tisotumab Vedotin | Zai Lab (Shanghai) Co., Ltd. | Solid Malignancies | 11/23 | 11/23 | | |
| Recruiting | 1 | 170 | RoW | SPH7485 | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumor | 12/27 | 12/27 | | |
| Recruiting | 1 | 216 | RoW | BAT8006 for Injection, Exatecan conjugate of recombinant humanized monoclonal antibody against folate receptor α for injection | Bio-Thera Solutions | Advanced Solid Tumors | 12/24 | 12/25 | | |
| Recruiting | 1 | 12 | RoW | HPV-T, Interleukin-2, IL-2 | BGI, China, Wuhan Union Hospital, China | Solid Tumor | 12/24 | 04/25 | | |
| Wu, Xiuhong |
NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer |
|
|
| Recruiting | 2 | 108 | RoW | Envafolimab+Lenvatinib, Envafolimab | 3D Medicines (Sichuan) Co., Ltd. | Advanced Endometrial Cancer | 08/24 | 10/24 | | |
| Guo, Qiaojuan |
NPC-CR01, NCT05128201: Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 63 | RoW | consolidative radiotherapy, local consolidative radiotherapy | Jiangxi Provincial Cancer Hospital | Oligometastatic Disease | 05/25 | 05/26 | | |
NCT06572293: Effect of Nurse-Led Individualized Follow-Up Intervention on Patients With Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | N/A | 250 | NA | Nurse-led intervention | Fujian Cancer Hospital | Nasopharyngeal Carcinoma | 12/25 | 12/30 | | |
